CompanyGraphAt a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $207.83M, lower than 95% of all stocks globally
- PositionPrice-to-book is 0.89×, lower than 95% of its Biotechnology peers (median 2.97×)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
207.83MUSDvs all stocks (USD)
Revenue (TTM)
36.68MUSDvs all stocks (USD)
Profit Margin
-159.99%vs Biotechnology peers
52-Week Change
-64.29%vs all stocks
Market Capitalization
207.83MUSDvs all stocks (USD)
Enterprise Value
-57.34MUSDvs all stocks (USD)
Forward P/E
-2.08xvs Biotechnology peers
Price to Sales (TTM)
5.67xvs Biotechnology peers
Price to Book (MRQ)
0.8878xvs Biotechnology peers
Enterprise to Revenue
-1.56xvs Biotechnology peers
Enterprise to EBITDA
0.9710xvs Biotechnology peers
Profit Margin
-159.99%vs Biotechnology peers
Operating Margin
-88.01%vs Biotechnology peers
Return on Assets (TTM)
-27.55%vs Biotechnology peers
Return on Equity (TTM)
-36.99%vs Biotechnology peers
Revenue (TTM)
36.68MUSDvs all stocks (USD)
Revenue per Share (TTM)
2.14USDUpdated Jul 19, 2026Quarterly Revenue Growth
1148.30%vs Biotechnology peers
Gross Profit (TTM)
-12.07MUSDvs all stocks (USD)
EBITDA (TTM)
-59.04MUSDvs all stocks (USD)
Net Income (TTM)
-58.69MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
740.54%vs Biotechnology peers
Operating Cash Flow (TTM)
-61.17MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-76.68MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
18.62MUSDFY2025 · Dec 31, 2025Operating Income
-76.81MUSDvs all stocks (USD)
Pre-tax Income
-76.83MUSDFY2025 · Dec 31, 2025Income Tax Expense
-142.00KUSDFY2025 · Dec 31, 2025Net Income
-76.68MUSDFY2025 · Dec 31, 2025EBIT
-76.81MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-76.49MUSDFY2025 · Dec 31, 2025Research & Development
53.76MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
41.68MUSDFY2025 · Dec 31, 2025EPS (Basic)
-4.48USDFY2025 · Dec 31, 2025EPS (Diluted)
-4.48USDFY2025 · Dec 31, 2025Basic Shares Outstanding
17.11MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
17.11MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-49.50MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-50.67MUSDFY2025 · Dec 31, 2025Free Cash Flow
-52.11MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
0.00USDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-49.50MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
323.00KUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
-142.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
7.68MUSDFY2025 · Dec 31, 2025Other Non-cash Items
572.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
0.00USDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
3.73MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-13.33MUSDFY2025 · Dec 31, 2025Capital Expenditures
-1.45MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-1.45MUSDFY2025 · Dec 31, 2025Other Financing Charges
42.57MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
42.57MUSDFY2025 · Dec 31, 2025Shares Outstanding
17.11MSharesUpdated Jul 19, 2026Float Shares
15.72MSharesUpdated Jul 19, 2026Shares Short
3.61MSharesUpdated Jul 19, 2026Short Ratio
15.40daysvs all stocks
% Held by Insiders
4.27%vs all stocks
% Held by Institutions
88.74%vs all stocks
Total Cash (MRQ)
267.85MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
15.66USDUpdated Jul 19, 2026Total Debt (MRQ)
2.68MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0115xvs Biotechnology peers
Current Ratio (MRQ)
13.04xvs Biotechnology peers
Book Value per Share (MRQ)
13.69USDUpdated Jul 19, 2026Total Assets
278.35MUSDvs all stocks (USD)
Total Current Assets
272.85MUSDFY2025 · Dec 31, 2025Total Liabilities
71.07MUSDFY2025 · Dec 31, 2025Total Non-current Assets
5.51MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
29.27MUSDFY2025 · Dec 31, 2025Total Current Liabilities
41.80MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
270.00MUSDFY2025 · Dec 31, 2025Accounts Payable
4.40MUSDFY2025 · Dec 31, 2025Short-term Debt
3.67MUSDFY2025 · Dec 31, 2025Deferred Revenue
21.64MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
574.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
17.00KUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
207.29MUSDvs all stocks (USD)
52-Week Low
11.40USDUpdated Jul 19, 202652-Week High
73.06USDUpdated Jul 19, 202652-Week Change
-64.29%vs all stocks
50-Day MA
12.77USDUpdated Jul 19, 2026200-Day MA
13.26USDUpdated Jul 19, 2026Avg 10-Day Volume
200.69KSharesUpdated Jul 19, 2026Avg 30-Day Volume
226.64KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-5.02USDUpdated Jul 19, 2026Other Income / Expense
-12.00KUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Price-to-book is 0.89×, lower than 95% of its Biotechnology peers (median 2.97×)Notable
Price-to-book: 0.89Industry median: 2.97Industry P5: 1.03Peers compared: 261
Financial Health
Altman Z-Score 1.91: grey zoneSignificant
Altman Z-Score: 1.91
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $207.83M, lower than 95% of all stocks globallySignificant
Market cap (USD): 207,833,562Global P5: 269,387,740.27
Companies that share the same coordination system — how they create, deliver, or capture value.
Hans Biomed Corp.
Tier 1ProductionApproval-Gated PipelineRule
Keros Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Genomictree Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Koa Shoji Holdings Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
NextBioMedical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Terrascend Corp.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Humedix Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Coherus Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Minerva Neurosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
ImmuneOncia Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Savannah Energy PLC
1 interpretationDecline With Range Expansion And Drawdown
Arko Petroleum Corp.
1 interpretationDecline With Range Expansion And Drawdown
Barem Ambalaj Sanayi ve Ticaret A.Ş.
1 interpretationDecline With Range Expansion And Drawdown